An Open-label, Single-arm, Phase IV Study Assessing the Immunogenicity and Safety of ZOSTAVAX® at Minimum Release Specification Approaching Expiry Potency in Subjects ≥50 Years Old.
Phase of Trial: Phase IV
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Varicella zoster virus vaccine live (Primary)
- Indications Herpes zoster
- Focus Pharmacodynamics
- Sponsors sanofi pasteur MSD
- 03 Jul 2012 Planned number of patients 95 added as reported by European Clinical Trials Database.
- 09 Dec 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 09 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.